BR112017025029A2 - ?novo fragmento fab de anticorpo ngf anti- humano?. - Google Patents

?novo fragmento fab de anticorpo ngf anti- humano?.

Info

Publication number
BR112017025029A2
BR112017025029A2 BR112017025029-2A BR112017025029A BR112017025029A2 BR 112017025029 A2 BR112017025029 A2 BR 112017025029A2 BR 112017025029 A BR112017025029 A BR 112017025029A BR 112017025029 A2 BR112017025029 A2 BR 112017025029A2
Authority
BR
Brazil
Prior art keywords
human ngf
ngf antibody
fragment
antibody fab
new anti
Prior art date
Application number
BR112017025029-2A
Other languages
English (en)
Japanese (ja)
Inventor
Tanaka Hirotsugu
Fujita Hirotada
Aoki Toshiaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112017025029A2 publication Critical patent/BR112017025029A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

resumo ?novo fragmento fab de anticorpo ngf anti-humano?. prover um fragmento fab de anticorpo ngf anti-humano superior que mantenha uma alta atividade neutralizante e que reduza efeitos colaterais sistêmicos que têm origem na exposição sistêmica, enquanto expressa um efeito de droga local, e meios para o tratamento de dor pós-operatória usando tal fragmento de anticorpo. um fragmento fab de anticorpo ngf anti-humano compreendendo um fragmento de cadeia pesada que consiste na sequência de aminoácido mostrada pela seq id no:5 e uma cadeia leve que consiste na sequência de aminoácido mostrada pela seq id no: 8.
BR112017025029-2A 2015-05-22 2016-05-20 ?novo fragmento fab de anticorpo ngf anti- humano?. BR112017025029A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015104806 2015-05-22
JP104806/2015 2015-05-22
PCT/JP2016/065099 WO2016190263A1 (ja) 2015-05-22 2016-05-20 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント

Publications (1)

Publication Number Publication Date
BR112017025029A2 true BR112017025029A2 (pt) 2018-08-07

Family

ID=57393503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025029-2A BR112017025029A2 (pt) 2015-05-22 2016-05-20 ?novo fragmento fab de anticorpo ngf anti- humano?.

Country Status (22)

Country Link
US (1) US11260124B2 (pt)
EP (1) EP3299461B1 (pt)
JP (1) JP6700620B2 (pt)
KR (1) KR102440054B1 (pt)
CN (1) CN107614683B (pt)
AR (1) AR104721A1 (pt)
AU (1) AU2016268625B2 (pt)
BR (1) BR112017025029A2 (pt)
CA (1) CA2986210C (pt)
CO (1) CO2017012397A2 (pt)
HK (1) HK1246349A1 (pt)
IL (1) IL255832B (pt)
MA (1) MA42138A (pt)
MX (1) MX2017014911A (pt)
MY (1) MY184164A (pt)
PH (1) PH12017502126A1 (pt)
RU (1) RU2729825C2 (pt)
SG (1) SG11201709589XA (pt)
TW (1) TWI706959B (pt)
UA (1) UA123209C2 (pt)
WO (1) WO2016190263A1 (pt)
ZA (1) ZA201708169B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164477A1 (en) * 2015-04-06 2016-10-13 Meso Scale Technologies, Llc. High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
NL2017890B1 (nl) * 2016-11-29 2018-06-11 Josh Ip Iii B V Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
CA2500901A1 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101504729B1 (ko) * 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
KR101298383B1 (ko) * 2005-01-24 2013-08-20 엘란 파마 인터내셔널 리미티드 Ｎｇｆ에 대한 특이적 결합 멤버
US9532943B2 (en) 2010-12-20 2017-01-03 Cormatrix Cardiovascular, Inc. Drug eluting patch for the treatment of localized tissue disease or defect
JP2007244601A (ja) 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
PT2187964E (pt) 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
PT2448970E (pt) 2009-05-04 2014-10-20 Abbvie Res B V Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
SG191737A1 (en) 2010-12-20 2013-08-30 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
KR101783929B1 (ko) * 2011-05-06 2017-10-11 넥스베트 오스트레일리아 피티와이 리미티드 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
US8986952B2 (en) * 2011-08-11 2015-03-24 Astellas Pharma Inc. Anti-human NGF antibody
EA201492163A1 (ru) 2012-06-08 2015-08-31 Гленмарк Фармасьютикалс С.А. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
AU2015362775B2 (en) 2014-12-17 2019-07-04 Dow Global Technologies Llc Viscoelastic polyurethane foam with aqueous polymer dispersion

Also Published As

Publication number Publication date
MX2017014911A (es) 2018-03-23
HK1246349A1 (zh) 2018-09-07
ZA201708169B (en) 2019-06-26
IL255832B (en) 2021-07-29
SG11201709589XA (en) 2017-12-28
EP3299461A4 (en) 2018-12-19
CA2986210A1 (en) 2016-12-01
EP3299461A1 (en) 2018-03-28
EP3299461B1 (en) 2023-03-29
CA2986210C (en) 2022-04-26
KR102440054B1 (ko) 2022-09-06
AR104721A1 (es) 2017-08-09
MY184164A (en) 2021-03-24
CO2017012397A2 (es) 2018-02-28
TW201713691A (zh) 2017-04-16
UA123209C2 (uk) 2021-03-03
AU2016268625B2 (en) 2022-01-27
IL255832A (en) 2018-01-31
US20180147281A1 (en) 2018-05-31
CN107614683B (zh) 2020-12-22
US11260124B2 (en) 2022-03-01
KR20180006391A (ko) 2018-01-17
AU2016268625A1 (en) 2017-12-07
JP6700620B2 (ja) 2020-05-27
CN107614683A (zh) 2018-01-19
PH12017502126A1 (en) 2018-05-07
JPWO2016190263A1 (ja) 2018-04-12
RU2017145071A (ru) 2019-06-24
MA42138A (fr) 2018-03-28
RU2729825C2 (ru) 2020-08-12
TWI706959B (zh) 2020-10-11
RU2017145071A3 (pt) 2019-10-17
WO2016190263A1 (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
CL2020003409A1 (es) Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154)
CL2020001575A1 (es) Anticuerpos anti-trem2 y métodos relacionados.
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
BR112019011689A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
UY36194A (es) Anticuerpos anti-tau humanizados
CU24498B1 (es) Anticuerpos de factor xi
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
PE20190737A1 (es) Anticuerpos anti-cd27
UA117364C2 (uk) Похідні аматоксину
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
BR112016026811A2 (pt) formulação de anticorpo
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
MX2018015721A (es) Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
AR104250A1 (es) Anticuerpo anti-notch4 humano
CO2018001599A2 (es) Un inhibidor de anticuerpo monoclonal de factor xiia
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
BR112017022073A2 (pt) método para purificação de proteína
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112017025029A2 (pt) ?novo fragmento fab de anticorpo ngf anti- humano?.
FI3891642T3 (fi) Menetelmä lähdekoodien luotettavuuden varmistamiseksi
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.